tolvaptan has been researched along with Cyst in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Fang, Q; Fu, K; Guo, D; He, Y; Liu, H; Su, L; Wang, J; Wang, P; Xie, Y; Xiong, X; Xu, P; Yin, L; Yuan, H; Zhang, H; Zhu, X | 1 |
| Hasegawa, E; Hoshino, J; Ikuma, D; Mizuno, H; Sawa, N; Sekine, A; Suwabe, T; Ubara, Y; Yamanouchi, M | 1 |
| Reiterová, J; Tesař, V | 1 |
| Aihara, M; Fujiki, H; Hattori, K; Isakari, Y; Mizuguchi, H; Nagano, K; Ohmoto, K; Takeshita, Y; Yamada, Y; Yamamoto, M; Yamamura, Y | 1 |
| Cadnapaphornchai, MA; Goldstein, SL; Greenbaum, LA; Guay-Woodford, LM; Liebau, MC; Litwin, M; Mekahli, D; Schaefer, F; Seeman, T | 1 |
| Bange, H; Dijkstra, KL; Kanhai, AA; Leonhard, WN; Peters, DJM; Price, LS; Verburg, L | 1 |
| Gaur, P; Gedroyc, W; Hill, P | 1 |
| Kitajima, M; Miura, S; Takenaka, T | 1 |
| Fujiki, H; Nivens, E; Pinto, CS; Reif, GA; Wallace, DP; Yamaguchi, T | 1 |
2 review(s) available for tolvaptan and Cyst
| Article | Year |
|---|---|
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
Topics: Animals; Apoptosis; Cysts; Humans; Phosphatidylinositol 3-Kinases; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2022 |
ADPKD-what the radiologist should know.
Topics: Antidiuretic Hormone Receptor Antagonists; Carcinoma, Renal Cell; Cysts; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Kidney Calculi; Kidney Neoplasms; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2019 |
7 other study(ies) available for tolvaptan and Cyst
| Article | Year |
|---|---|
Benzodiazepine Derivatives as Potent Vasopressin V
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzodiazepines; Cyclic AMP; Cysts; Humans; Kidney; Mice; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Vasopressins | 2022 |
Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
Topics: Antidiuretic Hormone Receptor Antagonists; Case-Control Studies; Cysts; Female; Humans; Kidney; Liver; Liver Diseases; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prognosis; Retrospective Studies; Tolvaptan | 2022 |
[Tolvaptan, a vasopressin V
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cyclic AMP; Cysts; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins | 2022 |
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Child; Cysts; Humans; Infant, Newborn; Kidney; Longitudinal Studies; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive; Tolvaptan | 2023 |
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Culture Techniques; Combined Modality Therapy; Cysts; Disease Progression; Humans; Kidney; Male; Mice; Pioglitazone; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Rats; Rats, Wistar; Tolvaptan | 2020 |
The management of polycystic liver disease by tolvaptan.
Topics: Abdomen; Adult; Antidiuretic Hormone Receptor Antagonists; Cysts; Female; Humans; Kidney; Liver; Liver Diseases; Tolvaptan; Tomography, X-Ray | 2020 |
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
Topics: Adult; Aged; Amiloride; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blotting, Western; Cell Proliferation; Cells, Cultured; Chlorides; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Diuretics; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Agents; Tolvaptan; Vasopressins | 2011 |